CRMD - CorMedix Inc logo

CorMedix Inc

CRMD
Rev 2062xtop 1%10Y
Compare CRMD Hold

CorMedix Inc. develops and commercializes therapeutic products focused on preventing and treating infectious diseases, primarily targeting catheter-related bloodstream infections with its antimicrobial solution, DefenCath, for patients undergoing hemodialysis.

โš•๏ธ Healthcare NASDAQ Listed 2010 $ USD
$1,000 invested 10 years ago โ†’$507today

Score Overview

1 Year
Score
Net Growth14.79%
Net TrendGrew
Net Income Consistencyโ€”
Rev Growth48.29%
Rev TrendGrew
Revenue Consistencyโ€”
5 Years
Score7.2
Net Growth8x
Net Trend60%
Net Income Consistencyโ€”
Rev Growth2420x
Rev Trend60%
Revenue Consistencyโ€”
10 Years
Score
Net Growth9x
Net Trend50%
Net Income Consistency
Rev Growth2062x
Rev Trend50%
Revenue Consistency
All Time
Scoreโ€”
Net Growth19x
Net Trend50%
Net Income Consistency
Rev Growthโ€”
Rev Trend54%
Revenue Consistency

Explore the 2021 public Archive ranking โ†’

Where CorMedix Inc has ranked, year by year

Measure
Fundamentals Window

Showing 10 years ranking history by Net Income Consistency.

Has not reached the top 50 on Net Income Consistency in any year we have ranked.

  • CRMD

2020: 85.5% ยท 2021: 96.6% ยท free through 2021 ยท longest runs

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-09
$ 7.38โ€”
1 Year2025-10-09
$ 11.00-32.91%
5 Years2021-10-08
$ 4.8751.54%
10 Years2016-10-07
$ 14.55-49.28%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 462M$ 187M$ 256M
2025$ 311M$ 163M$ 149M
2024$ 43M-$ 17M$ 51M
2023$ 0.00-$ 46M$ 76M
2022$ 65.41K-$ 29M$ 59M
2021$ 190.94K-$ 28M$ 65M
2020$ 239.23K-$ 22M$ 46M
2019$ 283.27K-$ 16M$ 28M
2018$ 429.8K-$ 26M$ 17M
2017$ 329.33K-$ 33M$ 11M
2016$ 224.1K-$ 24M$ 20M
2015$ 210.13K-$ 18M$ 35M
2014$ 189.27K-$ 20M$ 4M
2013-$ 9M$ 2M
2012$ 0.00-$ 3M$ 835.47K
2011$ 0.00-$ 6M$ 1M
IPO2010-$ 10M$ 8M
CRMD - CorMedix Inc logo

CorMedix Inc fundamental performance

Between 2020 and 2025, revenue grew from $ 239.23K to $ 311M and net income went from -$ 22M to $ 163M. Revenue increased in 3 of those 5 years; net income in 3.

CorMedix Inc currently holds a 5-year HDB Score of 7.2 out of 10. How the HDB Score is calculated.

Membership

Continue CRMDโ€™s history

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,126 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year ยท Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies